55110-65-1

Usage

Uses

Used in Organic Synthesis:
1-(1,4,5,6-tetrahydropyrimidin-2-yl)hydrazine is used as a building block for the synthesis of various bioactive compounds and pharmaceutical intermediates due to its unique chemical structure and reactivity.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(1,4,5,6-tetrahydropyrimidin-2-yl)hydrazine is utilized as a precursor for developing new drugs, taking advantage of its potential to form a wide range of biologically active molecules.
Used in Coordination Chemistry:
1-(1,4,5,6-tetrahydropyrimidin-2-yl)hydrazine is employed as a potential ligand in coordination chemistry, where its ability to form complexes with metal ions can be exploited for various applications.
Used in Organic Transformations:
As a reagent in organic transformations, 1-(1,4,5,6-tetrahydropyrimidin-2-yl)hydrazine is used to facilitate specific chemical reactions, contributing to the synthesis of complex organic molecules.

Upstream product

• 20112-81-6 2-(methylthio)-1,4,5,6-tetrahydropyrimidine 
• 2055-46-1 2-mercapto-3,4,5,6-tetrahydropyrimidine 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 1160359-97-6 C₁₆H₂₀N₆O₂ 

Relevant academic research and scientific papers

Synthesis, Antileishmanial Activity and In Silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes

Background: Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most se-vere, fatal in 95% of cases. The undesired side-effects from first-li

Aminoguanidine hydrazone derivatives as non-peptide NPFF1 receptor antagonists reverse opioid induced hyperalgesia

Neuropeptide FF receptors (NPFF1R and NPFF2R) and their endogenous ligand Neuropeptide FF have been shown previously to display anti-opioid properties and to play a critical role in the adverse effects associated with chronic administrations of opiates including the development of opioid-induced hyperalgesia and analgesic tolerance. In this work, we sought to identify novel NPFF receptors ligands by focusing our interest on a series of heterocycles as rigidified non-peptide NPFF receptor ligands, starting from already described aminoguanidine hydrazones (AGH's). Binding experiments and functional assays highlighted AGH 1n and its rigidified analog 2-amino-dihydropyrimidine 22e for in vivo experiments. As earlier shown with the prototypical dipeptide antagonist RF9, both 1n and 22e reduced significantly the long lasting fentanyl-induced hyperalgesia in rodents. Altogether these data indicate that AGH rigidification maintains nanomolar affinities for both NPFF receptors, while improving antagonist character towards NPFF1R.

Platinum chelates of 2-hydrazino-azoles

This disclosure describes platinum chelates of 2-hydrazino-1-aza (or 1,3-diaza,1-oxa-3-aza or 1-thia-3-aza)-1-cyclo-alkenes which possess activity as antitumor agents.